The news adds two concrete pillars to the Keytruda “patent wall”: (1) Phase 3 OptiTROP-Lung05 shows Keytruda + sac-TMT beats ...

Summit Therapeutics advances ivonescimab with late-stage NSCLC and CRC studies, with FDA review underway and new partnerships expanding its oncology reach.

Summit Therapeutics (SMMT) stock faced a downgrade at H.C. Wainwright after late-stage trial data for Merck’s (MRK) lung cancer drug sac-TMT. Read more here.

Merck shares rose after partner Kelun-Biotech reported positive late-stage trial results for a Keytruda combination treatment ...

Treatment with the TROP2 ADC sac-TMT led to a 70% objective response rate and progression-free survival was “significantly ...

Merck (MRK) stock gains as a cancer drug the company develops with Kelun-Biotech bests its Keytruda blockbuster in a ...

OSE Immunotherapeutics has shared phase 2 data on its neo-epitope vaccine candidate and Keytruda in ovarian cancer, linking ...

Sichuan Kelun-Biotech Biopharmaceutical said on Thursday its experimental treatment combined with ​partner Merck's Keytruda ...

Professional antigen-presenting cells—monocytes and macrophages—engulf these proteins, digest them into short peptide ...

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ('Kelun-Biotech' or the 'Company', 6990.HK) announced today that the Independent Data Monitoring Committee (IDMC) concluded that the Phase III ...

Exelixis EXEL announced a clinical development collaboration with pharma giant Merck & Co. MRK to evaluate its pipeline ...

Sacituzumab tirumotecan (sac-TMT) plus pembrolizumab versus pembrolizumab as first-line treatment for PD-L1 positive advanced non-small cell lung cancer (NSCLC): Results from the randomized, ...